Benzinga | Jun 15, 2021 11:54AM EDT

Eton Pharma Stock Is Trading Higher After FDA Approval For Rezipres

* The FDA has approved Eton Pharmaceuticals Inc's (NASDAQ:ETON) Rezipres (ephedrine hydrochloride injection) to treat clinically significant hypotension occurring in the setting of anesthesia.

* Rezipres is already available in Europe.

* The company currently owns or receives royalties from four FDA-approved products, including Alkindi Sprinkle, Biorphen, Rezipres, and Alaway Preservative Free, and has five additional products that have been submitted to the FDA.

* Price Action: ETON shares are up 7.06% at $6.98 during the market session on the last check Tuesday.